ABSTRACT BACKGROUND Angiotensin-(1-9) [Ang-(1-9)] is a novel peptide of the counter-regulatory axis of the renin-
is in clinical trials to treat diabetic foot ulcers and cancer (6, 7) , emphasizing translational approaches targeting the counter-regulatory RAAS axis.
Less studied than Ang-(1-7), the alternative counterregulatory RAAS peptide angiotensin-(1-9) [Ang-(1-9)]
reduces adverse cardiovascular remodeling in rat models of hypertension and MI following peptide administration via osmotic mini-pump (8-10).
Ang-(1-9) attenuates cardiomyocyte hypertrophy and cardiac fibrosis in hypertensive models; these effects are blocked by coadministration of the angiotensin type 2 receptor (AT 2 R) antagonist PD123,319, further supporting independent effects of Ang-(1-9) as a new counter-regulatory RAAS axis peptide (8, 11) .
Assessment of RAAS peptides as therapeutics
is limited by short circulatory half-life, requiring osmotic mini-pumps for sustained release in vivo in experimental models. Accordingly, alternative delivery strategies are required for clinical translation. Viral gene therapy is being pursued for HF, including clinical trials using adeno-associated virus (AAV) vector-mediated delivery of sarcoplasmic endoreticulum calcium adenosine triphosphatase 2a (SERCA2a), emphasizing safety and clinical utility (12) .
Angiotensin peptides are not produced from genes, but are generated extracellularly in the circulation.
Synthetic expression cassettes for Ang II, Ang-(1-7), and Ang-(1-9) have been utilized in transgenic models and in gene transfer approaches (13) (14) (15) . Here, for the first time, in vivo AAV-mediated gene transfer of Ang-(1-9) via a synthetic expression cassette has been utilized to study cardiac effects in a murine model of MI.
METHODS

Detailed methods are presented in the Online
Appendix. Briefly, an Ang-(1-9) expression cassette (13) was sub-cloned into plasmid adeno-associated virus-multiple cloning site (pAAV-MCS) and AAV9
vectors produced via standard protocols (16 Fattah et al.
Ang-(1-9) Cardiac Gene Therapy Ang-(1-9) Cardiac Gene Therapy D E C E M B E R 2 0 , 2 0 1 6 : 2 6 5 2 -6 6 following LAD ligation ( Figure 1A) . High enhanced GFP expression was observed throughout the myocardium at all time points ( Figure 1B) . Quantification of enhanced GFP expression in cardiac lysates revealed enhanced GFP expression was detectable at 1 week and increased at 4 and 8 weeks ( Figure 1C) . 36.9 AE 2.5%) (data not shown). However, in MI and MI/AAVGFP, scar thickness was 329 AE 25 mm and 276 AE 3.9 mm, respectively, whereas in MI/ AAVAng-(1-9), scar thickness was significantly increased versus MI/AAVGFP to 383 AE 14 mm (p < 0.05) ( Figure 5C ).
Quantitative polymerase chain reaction of levels of RAAS genes in cardiac complementary DNA revealed significantly increased ACE in all MI groups compared to sham, whereas ACE2 expression remained unchanged (Online Figures 2A and 2B) .
Furthermore, significantly increased AT 2 R expression
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Ang-(1-9) Cardiac Gene Therapy D E C E M B E R 2 0 , 2 0 1 6 : 2 6 5 2 -6 6 Figures 1 and 2 .
Ang-(1-9) Cardiac Gene Therapy TL ¼ tibia length; other abbreviations as in Figures 1 and 2 .
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in MI/AAVAng-(1-9) was observed, while the angiotensin type 1 receptors were significantly decreased in all MI groups (Online Figures 2C and 2D ). Figure 1 . Ang II production in the heart does not produce acute cardiac remodeling, whereas systemic infusion does (37) . Tissue-specific effects were also reported for Ang-(1-7) in MI in transgenic mice (38) , and lentiviral delivery of Ang-(1-7) in rat MI improved cardiac function (39) , supporting the concept that local cardiac Ang-(1-7) and Ang-(1-9) produce beneficial effects. Time (Min)
* †
Upon achieving maximum developed pressure, hearts were paced at 320 beats/min and allowed to reach steady state for 10 min before addition of 1 mmol/l Ang-(1-9). The protein kinase A inhibitor H89 (1 mmol/l) was perfused 10 min prior to adding Ang-(1-9) and was present throughout perfusion. (A) There were significant differences in (A) LV developed pressure compared to control hearts, but not in (B) the first derivative of LV developed pressured (dP/dt max ). Control n ¼ 5, Ang-(1-9) n ¼ 6, and H89 þ Ang-(1-9) n ¼ 5. *p <0.05 versus control hearts; †p <0.05 versus Ang-(1-9). Abbreviations as in Figure 1 .
Ang-(1-9) Cardiac Gene Therapy To gain further insight into potential mechanisms underlying the positive inotropic effects of Ang-(1-9), excitation contraction coupling was studied in isolated murine cardiomyocytes (normal and after MI) and the whole rat heart and hiPSC-CMs.
We demonstrated a direct inotropic effect of Ang-(1-9) Cardiac Gene Therapy D E C E M B E R 2 0 , 2 0 1 6 : 2 6 5 2 -6 6
